Loading
NASDAQHealthcareBiotechnology
Latest quote
$17.59
+$0.42 · +2.45%
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Previous close
$17.59
+$0.42 · +2.45%
Regular session · ET · Market data may be delayed.
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Day range
Current $17.59
52-week range
Current $17.59
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
27
Expensive
Sentiment
65
Bullish
Risk
57
Elevated Risk
Momentum
29
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Day range
Current $17.59
52-week range
Current $17.59
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 583.19K USD | 1.34M USD |
| Gross profit | — | — | — | 583.19K USD | 1.34M USD |
| Research and development | 537.67M USD | 132.42M USD | 455.27M USD | 43.01M USD | 63.12M USD |
| Selling, general, and administrative | 556.7M USD | 48.35M USD | 23.74M USD | 22.12M USD | 17.46M USD |
| Operating expenses | 1.09B USD | 180.51M USD | 478.23M USD | 60.22M USD | 65.07M USD |
| Interest income | 15.5M USD | 13.47M USD | 10.4M USD | 1.51M USD | — |
| Interest expense | — | 8.69M USD | 16.46M USD | 4.4M USD | 208.3K USD |
| Depreciation and amortization | 146K USD | 89K USD | 198K USD | 1.26M USD | 2.46M USD |
| Operating income | −1.09B USD | −180.51M USD | −478.23M USD | −59.63M USD | −63.73M USD |
| Net income | −1.08B USD | −176.77M USD | −482.37M USD | −65.17M USD | −65.52M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI63.26M0.64%9.87B USD0.35%$153.77+3.00%
Vanguard Morningstar Total Stock Market ETFVTI50.61M0.00%2.3T USD0.03%$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB36.47M0.02%185.3B USD0.03%$289.48+0.64%
Vanguard Extended Market ETFVXF24.6M0.03%95.4B USD0.05%$235+0.80%
Vanguard Morningstar Small-Cap Value ETFVBR23.17M0.03%68.2B USD0.05%$234.43+0.22%
iShares Biotechnology ETFIBB20.28M0.19%10.28B USD0.44%$206.49+3.00%
iShares Russell Mid-Cap Growth ETFIWP13.42M0.07%19.82B USD0.23%$143.1+1.56%
iShares Russell Mid-Cap ETFIWR9.87M0.02%56.32B USD0.18%$109.82+0.87%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Extended Market ETFVXFVanguard Morningstar Small-Cap Value ETFVBRiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPiShares Russell Mid-Cap ETFIWRAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
